US-based pharmaceutical firm Pfizer has reported positive top-line results from its Phase II study of Clostridium difficile (C. difficile) vaccine PF-06425090 to prevent C. difficile infection (CDI).

PF-06425090 is an investigational vaccine candidate designed with a functional antibody response to neutralise toxins A and B, the two disease-causing toxins generated by C. difficile.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Spore-forming pathogen C. difficile releases toxins that might lead to life-threatening infections such as diarrhea, pseudomembranous colitis, asymptomatic colonisation, toxic megacolon and intestinal perforation.

The randomised, placebo-controlled, observer-blinded Phase II study evaluated the safety, tolerability, and immunogenicity of the vaccine in more than 850 healthy adults aged 65 to 85.

“The randomised, placebo-controlled, observer-blinded Phase II study evaluated the safety, tolerability, and immunogenicity of the vaccine in more than 850 healthy adults aged 65 to 85.”

Pfizer vaccine research and development senior vice-president and head Kathrin Jansen said: “Despite improved infection control measures, C. difficile disease continues to rise, further augmenting an already urgent public health threat with particular negative impact on older adults.

“We are very encouraged by these interim immunogenicity and safety results demonstrating robust increases in vaccine-elicited neutralising antibodies to both toxins, that we believe could provide protection against C. difficile disease.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The study assessed two dose levels 100mcg and 200mcg of the vaccine candidate on two different three-dose vaccination schedules.

Based on the current data from the pre-planned interim analysis, the firm intends to initiate the Phase III trial for the vaccine in the first half of this year.

In August 2014, C. difficile vaccine received fast track designation from the US Food and Drug Administration (FDA).

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact